Disc Medicine (IRON) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.50B and a free-cash-flow yield of -6.5%. Nama's AI scorecard rates it Sell, 4.2 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 4.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Trailing · -29.7% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-20.7%
How far the last close sits under the highest price of the past five years.
Market cap
$3.50B
Trailing P/E
—
Price / book
4.7
Price / sales
—
FCF yield
-6.5%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
2.1
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
IRON earnings
Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$1.73).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
-$1.53
-$1.71
+10.5%
—
Q2 2026
Jul 30, 2026
-$1.54
-$1.77
+13.0%
$0
Q1 2026
May 5, 2026
-$1.65
-$1.73
+4.6%
$0
Q4 2025
Feb 26, 2026
-$1.62
-$1.70
+4.7%
$0
IRON analyst price target
Median target $122.00 from 12 analysts, ranging $92.00 – $170.00.
Nama's AI scorecard currently rates Disc Medicine Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IRON report earnings?
Disc Medicine's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$1.73.
What is the IRON price target?
The median analyst price target from 12 analysts is $122.00, with a range of $92.00 – $170.00.
Is IRON Shariah compliant?
Nama's AAOIFI-style screen reads Disc Medicine as Can't Tell. A figure the screen needs is missing, so it can't tell.